Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U0KW
|
||||
| Former ID |
DAP000070
|
||||
| Drug Name |
Ramelteon
|
||||
| Synonyms |
Rozerem; Ramelteon [USAN]; Rozerem (TN); TAK-375; Ramelteon (JAN/USAN/INN); Rozerem, TAK-375, Ramelteon; N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide; N-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Insomnia [ICD9: 307.41, 307.42, 327.0, 780.51, 780.52; ICD10:F51.0, G47.0] | Approved | [1], [2] | ||
| Circadian rhythm sleep disorder [ICD9: 327.3, 780.55; ICD10:G47.2] | Terminated | [1], [2] | |||
| Therapeutic Class |
Hypnotics and Sedatives
|
||||
| Company |
Takeda
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H21NO2
|
||||
| InChI |
InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1
|
||||
| InChIKey |
YLXDSYKOBKBWJQ-LBPRGKRZSA-N
|
||||
| CAS Number |
CAS 196597-26-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9368722, 12015157, 14823708, 14847999, 17396858, 26612945, 30413545, 46505923, 47810466, 50070191, 50070903, 50810551, 57399556, 71825382, 81065549, 85789647, 90342558, 92124722, 92307942, 92721412, 99437057, 103370203, 103838767, 104011788, 113442055, 117539034, 124757124, 124772078, 125163928, 126592922, 126627642, 126651547, 126667057, 129814520, 134337398, 135184679, 135651228, 136949090, 137005126, 142796849, 143496454, 152035160, 152164855, 152237728, 152258949, 160647794, 160964318, 162011666, 162184404, 163122411
|
||||
| SuperDrug ATC ID |
N05CH02
|
||||
| Target and Pathway | |||||
| Target(s) | Melatonin receptor | Target Info | Modulator | [3], [4] | |
| Melatonin receptor type 1B | Target Info | Modulator | [3], [4] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Circadian entrainmenthsa04080:Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| Reactome | Class A/1 (Rhodopsin-like receptors) | ||||
| G alpha (i) signalling eventsR-HSA-373076:Class A/1 (Rhodopsin-like receptors) | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Small Ligand GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1356). | ||||
| REF 3 | Ramelteon: a melatonin receptor agonist for the treatment of insomnia. J Postgrad Med. 2008 Jan-Mar;54(1):45-8. | ||||
| REF 4 | MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.